Literature DB >> 25183030

Forty years of the war against Ebola.

Lei Zhang1, Hao Wang.   

Abstract

Humans have been fighting against the Ebola virus disease (EVD) since its first outbreak in 1976 in southern Sudan and Yambuku in Zaire which lies on the Ebola River. According to the data from the World Health Organization (WHO, 2014b), the first outbreak claimed 431 lives in 1976, and the disease awoke transiently in Sudan three years later and then disappeared for 15 years afterwards. Following that, large outbreaks appeared in 1995 in Zaire with 250 deaths of people, 2001-2002 in Uganda with 224 deaths, 2002-2003 in Congo with 128 deaths, and 2007 in Congo with 187 deaths. In 2014, the most severe and complicated outbreak swept through the West African countries having already taken 1069 lives, with the situation seeming to be out of control. To date, there have been 15 outbreaks in Africa, which have caused 4362 infected cases and claimed 2659 lives. The pandemics of Ebola show obvious independence from any season. Humans are generally susceptible to the Ebola virus without gender or age variation. The natural reservoir of the Ebola virus still remains unclear. During the past 40 years or so, the EVD disappeared after an outbreak in one region and erupted in another region without any warning. The difficulty in understanding the spreading pattern of Ebola was compared to that of the wave-particle duality of light.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25183030      PMCID: PMC4162877          DOI: 10.1631/jzus.B1400222

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  16 in total

1.  Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro.

Authors:  M Gupta; S Mahanty; R Ahmed; P E Rollin
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

2.  Ebola--a growing threat?

Authors:  Heinz Feldmann
Journal:  N Engl J Med       Date:  2014-05-07       Impact factor: 91.245

3.  Ebola haemorrhagic fever in Zaire, 1976.

Authors: 
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

4.  T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus.

Authors:  Andrew S Kondratowicz; Nicholas J Lennemann; Patrick L Sinn; Robert A Davey; Catherine L Hunt; Sven Moller-Tank; David K Meyerholz; Paul Rennert; Robert F Mullins; Melinda Brindley; Lindsay M Sandersfeld; Kathrina Quinn; Melodie Weller; Paul B McCray; John Chiorini; Wendy Maury
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-02       Impact factor: 11.205

5.  Fruit bats as reservoirs of Ebola virus.

Authors:  Eric M Leroy; Brice Kumulungui; Xavier Pourrut; Pierre Rouquet; Alexandre Hassanin; Philippe Yaba; André Délicat; Janusz T Paweska; Jean-Paul Gonzalez; Robert Swanepoel
Journal:  Nature       Date:  2005-12-01       Impact factor: 49.962

6.  Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.

Authors:  K Mupapa; M Massamba; K Kibadi; K Kuvula; A Bwaka; M Kipasa; R Colebunders; J J Muyembe-Tamfum
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

7.  Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections.

Authors:  P B Jahrling; T W Geisbert; J B Geisbert; J R Swearengen; M Bray; N K Jaax; J W Huggins; J W LeDuc; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

Review 8.  Evasion of interferon responses by Ebola and Marburg viruses.

Authors:  Christopher F Basler; Gaya K Amarasinghe
Journal:  J Interferon Cytokine Res       Date:  2009-09       Impact factor: 2.607

9.  Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008.

Authors:  Joseph F Wamala; Luswa Lukwago; Mugagga Malimbo; Patrick Nguku; Zabulon Yoti; Monica Musenero; Jackson Amone; William Mbabazi; Miriam Nanyunja; Sam Zaramba; Alex Opio; Julius J Lutwama; Ambrose O Talisuna; Sam I Okware
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

10.  Development of a new vaccine for the prevention of Lassa fever.

Authors:  Thomas W Geisbert; Steven Jones; Elizabeth A Fritz; Amy C Shurtleff; Joan B Geisbert; Ryan Liebscher; Allen Grolla; Ute Ströher; Lisa Fernando; Kathleen M Daddario; Mary C Guttieri; Bianca R Mothé; Tom Larsen; Lisa E Hensley; Peter B Jahrling; Heinz Feldmann
Journal:  PLoS Med       Date:  2005-06-28       Impact factor: 11.069

View more
  5 in total

1.  Non-specific anti-viral approach towards Ebola virus infection: a comment on "Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis".

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

2.  A case report on indirect transmission of human rabies.

Authors:  Jian-yong Zhu; Jian Pan; Yuan-qiang Lu
Journal:  J Zhejiang Univ Sci B       Date:  2015-11       Impact factor: 3.066

3.  Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis.

Authors:  Lei Zhang; Hao Wang; Yi-qing Zhang
Journal:  J Zhejiang Univ Sci B       Date:  2015-01       Impact factor: 3.066

4.  Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: An In silico Approach.

Authors:  Shruti Baikerikar
Journal:  Pharmacognosy Res       Date:  2017-12

Review 5.  Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.

Authors:  Olivier Tshiani Mbaya; Philippe Mukumbayi; Sabue Mulangu
Journal:  Front Immunol       Date:  2021-08-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.